These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38812020)

  • 1. Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab.
    Luna-Alcala S; Espejel-Guzmán A; Lerma C; Leon P; Guerra EC; Fernández JRE; Martinez-Dominguez P; Serrano-Roman J; Cabello-Ganem A; Aparicio-Ortiz AD; Keirns C; Lerma A; Ana-Bayona MJS; Espinola-Zavaleta N
    Cardiooncology; 2024 May; 10(1):32. PubMed ID: 38812020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?
    Guimarães SL; Brandão SC; Andrade LR; Maia RJ; Markman Filho B
    Arq Bras Cardiol; 2015 Sep; 105(3):228-34. PubMed ID: 26176188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
    Feng Y; Qin Z; Yang Z
    J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an 18-Week Integrated Yoga Program on Cardiac Autonomic Function in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Randomized Controlled Trial.
    Inbaraj G; Udupa K; Raghavendra RM; Ram A; Patil S; Rajeswaran J; Nandakumar KK; Belur S; Arjun K; Govindaraj R; Bayari SK; Sathyaprabha TN
    Integr Cancer Ther; 2023; 22():15347354231168795. PubMed ID: 37594042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review.
    Antunes P; Esteves D; Nunes C; Amarelo A; Fonseca-Moutinho J; Afreixo V; Costa H; Alves A; Joaquim A
    Syst Rev; 2019 Oct; 8(1):239. PubMed ID: 31651372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
    Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
    Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
    PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
    Zhang L; Wang Y; Meng W; Zhao W; Tong Z
    Sci Rep; 2022 Aug; 12(1):14312. PubMed ID: 35995984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
    Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis.
    Li L; Jiang X; Xie Q
    Echocardiography; 2023 Apr; 40(4):306-317. PubMed ID: 36859694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab.
    Gulati G; Zhang KW; Scherrer-Crosbie M; Ky B
    Curr Heart Fail Rep; 2014 Dec; 11(4):366-73. PubMed ID: 25079445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC).
    Zito C; Manganaro R; Cusmà Piccione M; Madonna R; Monte I; Novo G; Mercurio V; Longobardo L; Cadeddu Dessalvi C; Deidda M; Pagliaro P; Spallarossa P; Costantino R; Santarpia M; Altavilla G; Carerj S; Tocchetti CG
    Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):406-415. PubMed ID: 33432333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
    Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
    ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.